BjornevikKCorteseMHealyBC, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science2022; 375(6578): 296–301.
2.
VietzenHBergerSMKühnerLM, et al. Ineffective control of Epstein-Barr-virus-induced autoimmunity increases the risk for multiple sclerosis. Cell2023; 186(26): 5705–5718.e13.
3.
MaplePAAscherioACohenJI, et al. The potential for EBV vaccines to prevent multiple sclerosis. Front Neurol2022; 13: 887794.
4.
SmithCKhannaR. Adoptive T-cell therapy targeting Epstein–Barr virus as a treatment for multiple sclerosis. Clin Transl Immunology2023; 12(3): e1444.
5.
AinsworthC. Building a better lymphoma vaccine. Nature2018; 563(7731): S52–S54.
6.
WinterJRJacksonCLewisJE, et al. Predictors of Epstein-Barr virus serostatus and implications for vaccine policy: A systematic review of the literature. J Glob Health2020; 10(1): 010404.
7.
MackenzieISMorantSVBloomfieldGA, et al. Incidence and prevalence of multiple sclerosis in the UK 1990-2010: A descriptive study in the General Practice Research Database. J Neurol Neurosurg Psychiatry2014; 85(1): 76–84.
8.
HedströmAK. Risk factors for multiple sclerosis in the context of Epstein-Barr virus infection. Front Immunol2023; 14: 1212676.
9.
HandelAEWilliamsonAJDisantoG, et al. An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis. PLoS ONE2010; 5(9): e12496.
10.
RostgaardKNielsenNMMelbyeM, et al. Siblings reduce multiple sclerosis risk by preventing delayed primary Epstein–Barr virus infectionBrain2023; 146(5): 1993–2002.
11.
JonsDSundströmPAndersenO. Targeting Epstein-Barr virus infection as an intervention against multiple sclerosis. Acta Neurol Scand2015; 131(2): 69–79.
